| Autor: |
Pasvolsky, Oren, Saliba, Rima M., Masood, Adeel, Mohamedi, Ali H., Tanner, Mark R., Bashir, Qaiser, Srour, Samer, Saini, Neeraj, Ramdial, Jeremy, Nieto, Yago, Lee, Hans C., Patel, Krina K., Kebriaei, Partow, Thomas, Sheeba K., Weber, Donna M., Orlowski, Robert Z., Shpall, Elizabeth J., Champlin, Richard E., Qazilbash, Muzaffar H. |
| Předmět: |
|
| Zdroj: |
British Journal of Haematology; May2023, Vol. 201 Issue 4, pe37-e41, 5p |
| Abstrakt: |
In the subset of patients aged >=50 ( I N i = 2293), most baseline characteristics were similar between the two genders, though more female patients had a lower performance score (KPS <= 80) at AHCT compared to males (43% vs. 38%; I p i = 0.01) (Table S2). Multiple myeloma (MM) is a common haematological malignancy, accounting for 1.8% of all new cases of cancer in the United States.[1] The prevalence of MM is slightly higher in men compared to women, 8.8 versus 5.7 new cases per 100 000 persons per year, respectively, yet the impact of gender on outcomes of patients with MM remains unclear, with contradictory reports in the literature.[[2], [4]] Specifically, the impact of gender on outcomes after high-dose chemotherapy and autologous haematopoietic stem cell transplantation (AHCT) has not been studied in detail. After a median follow-up among surviving patients of 53 (1-262) months, rates of disease progression were similar in both genders ([57%, 95% Confidence Interval (CI) 54-60] in females and [58%, 95% CI 55-61] in males; HR 0.9 [95% CI 0.9-1.1]; I p i = 0.7). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text